Mankind Pharma’s Board of Directors has approved the unaudited standalone and consolidated financial results for the quarter and nine months ending December 31, 2025. The Board convened on February 3, 2026, to review and approve these financials. The results are accompanied by a limited review report from Joint Statutory Auditors. Key details from the financial performance are included in the company’s official statement.
Q3 Financial Performance Review
Mankind Pharma’s Board of Directors has officially approved the unaudited financial results for Q3 2026. The decision was made during a board meeting held on February 3, 2026. This includes both standalone and consolidated figures for the quarter and the nine-month period ending December 31, 2025.
Auditor Review and Board Approval
The financial results are accompanied by a Limited Review Report issued by both M/s. S. R. Batliboi & Co. LLP and M/s. Bhagi Bhardwaj Gaur & Co., the Joint Statutory Auditors. The board has formally reviewed and given its approval to the financial outcomes, ensuring they align with regulatory requirements.
Key Financial Figures (Standalone)
Revenue from Operations: Increased to ₹2,632.68 crore for Q3 2026.
Profit After Tax: Reached ₹449.47 crore for the quarter.
Earnings Per Share: Reported as ₹10.89 per share for Q3.
Total revenue for the nine-month period reached ₹7,839.36 crore, and profit after tax stood at ₹1,329.04 crore.
Significant Matters
Comparative figures for previous periods have been restated to reflect adjustments due to business combinations. There is an ongoing income tax proceeding, with the company appealing against orders received for relevant assessment years.
Segment Reporting
Mankind Pharma operates primarily in the pharmaceuticals sector. As such, the Company has one reportable segment i.e. ‘Pharmaceuticals’, so additional segment reporting disclosures are not applicable.
Auditor Notes
Auditors highlighted uncertainties regarding ongoing income tax proceedings and noted the restatement of financials due to business combinations. Their review and opinions did not reflect modifications related to these matters.
Source: BSE
